Edgewise Therapeutics, (id:8001 EWTX)
32.20 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 1:01:05 PM)
Exchange closed, opens in 20 hours 28 minutes
About Edgewise Therapeutics,
Market Capitalization 2.98B
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Headquarters (address) |
1715 38th Street Boulder 80301 CO United States |
| Phone | 720 262 7002 |
| Website | https://www.edgewisetx.com |
| Employees | 97 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | EWTX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 5.93 - 38.12 |
| Market Capitalization | 2.98B |
| P/E trailing | -20.51 |
| P/E forward | -16.99 |
| Price/Book | 6.07 |
| Beta | 0.153 |
| EPS | -1.50 |
| EPS United States (ID:6, base:3402) | 24.22 |